Therefore, the p21WAF1/p53 immunophenotype seems to be a better predictor of DFS than loss of MMR protein expression in patients with stage B and C Astler-Coller CRC subjected to adjuvant 5FU-based therapy. The gene discussed is TP53; the disease is colorectal carcinoma.